Fast-track status will allow Solid Biosciences to have more frequent meetings with the FDA throughout the treatment-development process and, potentially, get the product to patients faster than would ...

An experimental gene therapy developed by Lexeo Therapeutics has shown early promise in treating one of the most serious complications of the rare neurodegenerative disorder, Friedreich's ataxia (FA).

Solid Biosciences Inc. has gained IND clearance from the FDA for SGT-212 for the treatment of Friedreich’s ataxia (FA). BioWorld Science Regulatory Neurology/psychiatric Gene therapy FDA IND Popular ...

Cerebellar ataxia is a neurological disorder of the ... The aim is to develop a therapy that only targets the pathogenic ...

An FDA-approved medication can now treat Friedreich's ataxia, but health plan barriers and formulary exclusions keep many patients from receiving it.

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.

Solid Biosciences’ AAV-based gene therapy candidate, SGT-212 for Friedreich’s ataxia receives US FDA fast track designation: Charlestown, Massachusetts Thursday, January 23, 2 ...

In such cases, an inability to balance is a symptom known as ataxia. But ataxia can also be its own condition or disease. Start the day smarter. Get all the news you need in your inbox each morning.

Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE ...

(SLDB), Tuesday announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SGT-212 for the treatment of Friedreich's ataxia (FA), a ...